All Stories

  1. Childhood obesity in relation to poor asthma control and exacerbation: a meta-analysis

    Article • European Respiratory Journal, September 2016, European Respiratory Society (ERS)

    Dr Anke H Maitland-van der Zee

  2. Genotype-guided coumarin dosing: where are we now and where do we need to go next?

    Article • Expert Opinion on Drug Metabolism & Toxicology, January 2015, Informa Healthcare

    Dr Anke H Maitland-van der Zee

  3. The COAG and EU-PACT Trials: What is the Clinical Benefit of Pharmacogenetic-Guided Coumarin Dosing During Therapy Initiation?

    Article • Current Molecular Medicine, August 2014, Bentham Science Publishers

    Dr Anke H Maitland-van der Zee

  4. Beliefs about medicines in Dutch acenocoumarol and phenprocoumon users

    Article • British Journal of Clinical Pharmacology, July 2014, Wiley

    Dr Anke H Maitland-van der Zee

  5. Evaluation of the effects of single‐nucleotide polymorphisms in CYP3A4 and CYP4F2 on stable phenprocoumon and acenocoumarol maintenance doses: reply

    Article • Journal of Thrombosis and Haemostasis, July 2014, Elsevier

    Dr Anke H Maitland-van der Zee

  6. Patients Benefit From Genetics-Guided Coumarin Anticoagulant Therapy

    Article • Clinical Pharmacology & Therapeutics, July 2014, Wiley

    Dr Anke H Maitland-van der Zee

  7. Phenotype Standardization of Angioedema in the Head and Neck Region Caused by Agents Acting on the Angiotensin System

    Article • Clinical Pharmacology & Therapeutics, June 2014, Wiley

    Dr Anke H Maitland-van der Zee

  8. Phenotype Standardization for Statin-Induced Myotoxicity

    Article • Clinical Pharmacology & Therapeutics, June 2014, Wiley

    Dr Anke H Maitland-van der Zee

  9. Application of routine electronic health record databases for pharmacogenetic research

    Article • Journal of Internal Medicine, May 2014, Wiley

    Dr Anke H Maitland-van der Zee

  10. Pharmacogenetic analysis of GLCCI1 in three north European pediatric asthma populations with a reported use of inhaled corticosteroids

    Article • Pharmacogenomics, April 2014, Future Medicine

    Dr Anke H Maitland-van der Zee

  11. Pharmacogenetic‐guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon

    Article • British Journal of Clinical Pharmacology, March 2014, Wiley

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  12. Pharmacogenomics: Advancing Evidence-Based Personalized Medicine

    Article • February 2014, Taylor & Francis

    Dr Anke H Maitland-van der Zee

  13. The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study

    Article • Pharmacogenetics and Genomics, January 2014, Wolters Kluwer Health

    Dr Anke H Maitland-van der Zee

  14. A Randomized Trial of Genotype-Guided Dosing of Acenocoumarol and Phenprocoumon

    Article • New England Journal of Medicine, December 2013, New England Journal of Medicine (NEJM/MMS)

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  15. A Randomized Trial of Genotype-Guided Dosing of Warfarin

    Article • New England Journal of Medicine, December 2013, New England Journal of Medicine (NEJM/MMS)

    Dr Anke H Maitland-van der Zee

  16. ADRB2 Arg16 and the need for collaboration in childhood asthma pharmacogenomics

    Article • Pharmacogenomics, December 2013, Future Medicine

    Dr Anke H Maitland-van der Zee

  17. Arg16 ADRB2 genotype increases the risk of asthma exacerbation in children with a reported use of long-acting β 2 -agonists: results of the pacman cohort

    Article • Pharmacogenomics, December 2013, Future Medicine

    Dr Anke H Maitland-van der Zee

  18. Secretory Phospholipase A2-IIA and Cardiovascular Disease

    Article • Journal of the American College of Cardiology, November 2013, Elsevier

    Dr Anke H Maitland-van der Zee

  19. Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with coronary arte...

    Article • Pharmacogenetics and Genomics, October 2013, Wolters Kluwer Health

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  20. Cholesteryl Ester Transfer Protein Polymorphisms, Statin Use, and Their Impact on Cholesterol Levels and Cardiovascular Events

    Article • Clinical Pharmacology & Therapeutics, September 2013, Wiley

    Dr Anke H Maitland-van der Zee

  21. Clinical utility of asthma biomarkers: from bench to bedside

    Article • Biologics Targets & Therapy, August 2013, Taylor & Francis

    Dr Bart Hilvering, Dr Anke H Maitland-van der Zee

  22. Pharmacogenetics of statins

    Article • Clinical Biochemistry, August 2013, Elsevier

    Dr Anke H Maitland-van der Zee

  23. Inflammatory phenotypes underlying uncontrolled childhood asthma despite inhaled corticosteroid treatment: rationale and design of the PACMAN2 study

    Article • BMC Pediatrics, June 2013, Springer Science + Business Media

    Dr Anke H Maitland-van der Zee

  24. Cost–effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation

    Article • Pharmacogenomics, June 2013, Future Medicine

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  25. Evaluation of the effects of single-nucleotide polymorphisms in CYP3A4 and CYP4F2 on stable phenprocoumon and acenocoumarol maintenance doses

    Article • Journal of Thrombosis and Haemostasis, June 2013, Elsevier

    Dr Anke H Maitland-van der Zee

  26. Corrigendum to: ‘Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data’ [Eur Heart J (2011) 32 (15): 1909-1917, doi:10.1093/eurheartj/ehr116]

    Article • European Heart Journal, April 2013, European Society of Cardiology

    Dr Anke H Maitland-van der Zee

  27. Pharmacogenetics of ACE inhibitor-induced angioedema and cough: a systematic review and meta-analysis

    Article • Pharmacogenomics, February 2013, Future Medicine

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  28. Pharmacogenetics and Individualized Therapy. Edited by Anke‐Hilse Maitland‐van der Zee and Ann K. Daly

    Article • ChemMedChem, January 2013, Wiley

    Dr Anke H Maitland-van der Zee

  29. Evaluation of the effect of genetic variations inGATA-4on the phenprocoumon and acenocoumarol maintenance dose

    Article • Pharmacogenomics, December 2012, Future Medicine

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  30. Long‐term anticoagulant effects of CYP2C9 and VKORC1 genotypes in phenprocoumon users

    Article • Journal of Thrombosis and Haemostasis, December 2012, Elsevier

    Dr Anke H Maitland-van der Zee

  31. The effect of omeprazole and esomeprazole on the maintenance dose of phenprocoumon

    Article • British Journal of Clinical Pharmacology, November 2012, Wiley

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  32. Evaluation of the effect of statin use on the acenocoumarol and phenprocoumon maintenance dose

    Article • Drug Metabolism and Drug Interactions, September 2012, De Gruyter

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  33. Cost–effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs

    Article • Pharmacogenomics, September 2012, Future Medicine

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  34. Vascular Endothelial Growth Factor Pathway Polymorphisms as Prognostic and Pharmacogenetic Factors in Cancer: A Systematic Review and Meta-analysis

    Article • Clinical Cancer Research, August 2012, American Association for Cancer Research (AACR)

    Dr Anke H Maitland-van der Zee

  35. Validation of the acenocoumarol EU-PACT algorithms: similar performance in the Rotterdam Study cohort as in the original study

    Article • Pharmacogenomics, August 2012, Future Medicine

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  36. Exhaled NO is a poor marker of asthma control in children with a reported use of asthma medication: a pharmacy‐based study

    Article • Pediatric Allergy and Immunology, May 2012, Wiley

    Dr Anke H Maitland-van der Zee

  37. Conference Scene: 5th Anniversary Meeting of the European Research Network Pharmacogenetics/Pharmacogenomics

    Article • Pharmacogenomics, May 2012, Future Medicine

    Dr Anke H Maitland-van der Zee

  38. Added value of pharmacogenetic testing in predicting statin response: results from the REGRESS trial

    Article • The Pharmacogenomics Journal, May 2012, Springer Science + Business Media

    Dr Anke H Maitland-van der Zee

  39. An evaluation of gene–gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol

    Article • Journal of Thrombosis and Haemostasis, May 2012, Elsevier

    Dr Anke H Maitland-van der Zee

  40. Pharmacogenetics and Individualized Therapy

    Article • April 2012, Wiley

    Dr Anke H Maitland-van der Zee

  41. Pharmacogenetics: Possibilities and Pitfalls

    Article • April 2012, Wiley

    Dr Anke H Maitland-van der Zee

  42. Cardiovascular Pharmacogenetics

    Article • April 2012, Wiley

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  43. Pharmacogenetics of Asthma and COPD

    Article • April 2012, Wiley

    Dr Anke H Maitland-van der Zee

  44. Long‐term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users

    Article • Journal of Thrombosis and Haemostasis, April 2012, Elsevier

    Dr Anke H Maitland-van der Zee

  45. Large-Scale Gene-Centric Meta-Analysis across 39 Studies Identifies Type 2 Diabetes Loci

    Article • The American Journal of Human Genetics, April 2012, Elsevier

    Dr Anke H Maitland-van der Zee

  46. Future of Pharmacogenetics in Cardiovascular Diseases

    Article • March 2012, IntechOpen

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  47. Large-Scale Gene-Centric Meta-Analysis across 39 Studies Identifies Type 2 Diabetes Loci

    Article • The American Journal of Human Genetics, March 2012, Elsevier

    Dr Anke H Maitland-van der Zee

  48. Variation atGLCCI1andFCER2: one step closer to personalized asthma treatment

    Article • Pharmacogenomics, February 2012, Future Medicine

    Dr Anke H Maitland-van der Zee

  49. Genotyping for CYP2C9 and VKORC1 alleles by a novel point of care assay with HyBeacon® probes

    Article • Clinica Chimica Acta, November 2011, Elsevier

    Dr Anke H Maitland-van der Zee

  50. FCER2 T2206C variant associated with chronic symptoms and exacerbations in steroid-treated asthmatic children

    Article • Allergy, September 2011, Wiley

    Dr Anke H Maitland-van der Zee

  51. Implementation of pharmacogenetics in clinical practice is challenging

    Article • Pharmacogenomics, September 2011, Future Medicine

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  52. Inhaled corticosteroid adherence in paediatric patients: the PACMAN cohort study

    Article • Pharmacoepidemiology and Drug Safety, August 2011, Wiley

    Dr Anke H Maitland-van der Zee

  53. Asthma Symptoms in Pediatric Patients: Differences throughout the Seasons

    Article • Journal of Asthma, August 2011, Taylor & Francis

    Dr Anke H Maitland-van der Zee

  54. Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MI

    Article • Atherosclerosis, August 2011, Elsevier

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  55. Limited agreement between current and long‐term asthma control in children: the PACMAN cohort study

    Article • Pediatric Allergy and Immunology, July 2011, Wiley

    Dr Anke H Maitland-van der Zee

  56. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data

    Article • European Heart Journal, June 2011, European Society of Cardiology

    Dr Anke H Maitland-van der Zee

  57. Biomarkers of therapy responsiveness in asthma: pitfalls and promises

    Article • Clinical & Experimental Allergy, April 2011, Wiley

    Dr Anke H Maitland-van der Zee

  58. Pharmacogenetics: From Bench to Byte— An Update of Guidelines

    Article • Clinical Pharmacology & Therapeutics, March 2011, Wiley

    Dr Anke H Maitland-van der Zee

  59. Uncontrolled asthma at age 8: The importance of parental perception towards medication

    Article • Pediatric Allergy and Immunology, February 2011, Wiley

    Dr Anke H Maitland-van der Zee

  60. Asthma medication use in infancy: determinants related to prescription of drug therapy

    Article • Family Practice, February 2011, Oxford University Press (OUP)

    Dr Anke H Maitland-van der Zee

  61. From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics

    Article • International Journal of Clinical Pharmacy, February 2011, Springer Science + Business Media

    Dr Anke H Maitland-van der Zee

  62. CYP2C19 and ABCB1 genes and individualized treatment with clopidogrel

    Article • Pharmacogenomics, February 2011, Future Medicine

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  63. Practical recommendations for pharmacogenomics-based prescription: 2010 ESF–UB Conference on Pharmacogenetics and Pharmacogenomics

    Article • Pharmacogenomics, January 2011, Future Medicine

    Dr Anke H Maitland-van der Zee, Dr Mikko Niemi

  64. Genetic variation in the renin—angiotensin system, use of renin—angiotensin system inhibitors and the risk of myocardial infarction

    Article • Journal of the Renin-Angiotensin-Aldosterone System, December 2010, SAGE Publications

    Dr Anke H Maitland-van der Zee

  65. Variants of ADAMTS1 modify the effectiveness of statins in reducing the risk of myocardial infarction

    Article • Pharmacogenetics and Genomics, December 2010, Wolters Kluwer Health

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  66. From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics

    Article • International Journal of Clinical Pharmacy, November 2010, Springer Science + Business Media

    Dr Anke H Maitland-van der Zee

  67. High agreement between parental reported inhaled corticosteroid use and pharmacy prescription data

    Article • Pharmacoepidemiology and Drug Safety, October 2010, Wiley

    Dr Anke H Maitland-van der Zee

  68. SNP s: Single Nucleotide Polymorphisms and Pharmacogenomics: Individually Designed Drug Therapy

    Article • September 2010, Wiley

    Dr Anke H Maitland-van der Zee

  69. Pharmacogenetics of Anti-Inflammatory Therapy in Asthma: Corticosteroids and Leukotriene Antagonists

    Article • Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, September 2010, Bentham Science Publishers

    Dr Anke H Maitland-van der Zee

  70. Pharmacogenetic interactions betweenABCB1andSLCO1B1tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction

    Article • Pharmacogenomics, August 2010, Future Medicine

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  71. Clinical and economic consequences of pharmacogenetic-guided dosing of warfarin

    Article • Expert Review of Pharmacoeconomics & Outcomes Research, August 2010, Taylor & Francis

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  72. Statin Prescribing in the Elderly in the Netherlands

    Article • Drugs & Aging, July 2010, Springer Science + Business Media

    Dr Anke H Maitland-van der Zee

  73. A systematic review of cost–effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives

    Article • Pharmacogenomics, July 2010, Future Medicine

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  74. Patterns of asthma medication use: early asthma therapy initiation and asthma outcomes at age 8†

    Article • Pharmacoepidemiology and Drug Safety, April 2010, Wiley

    Dr Anke H Maitland-van der Zee

  75. Single nucleotide polymorphisms in genes that are associated with a modified response to statin therapy: the Rotterdam Study

    Article • The Pharmacogenomics Journal, March 2010, Springer Science + Business Media

    Dr Anke H Maitland-van der Zee

  76. Asthma Therapy During the First 8 Years of Life: A PIAMA Cohort Study

    Article • Journal of Asthma, February 2010, Taylor & Francis

    Dr Anke H Maitland-van der Zee

  77. Methodological and statistical issues in pharmacogenomics

    Article • Journal of Pharmacy and Pharmacology, February 2010, Oxford University Press (OUP)

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  78. Pharmacogenetics and pharmacogenomics: practical applications in routine medical practice

    Article • Genome Medicine, January 2010, Springer Science + Business Media

    Dr Anke H Maitland-van der Zee

  79. Pharmacogenetics and the Pharmaceutical Industry

    Article • Current Pharmaceutical Design, January 2010, Bentham Science Publishers

    Dr Anke H Maitland-van der Zee

  80. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design

    Article • Pharmacogenomics, October 2009, Future Medicine

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  81. Determinants of DNA yield and purity collected with buccal cell samples

    Article • European Journal of Epidemiology, September 2009, Springer Science + Business Media

    Dr Anke H Maitland-van der Zee

  82. Conference Scene: Pharmacogenomics at the second PharmSciFair 2009: adverse drug reactions and clinical implementation

    Article • Pharmacogenomics, September 2009, Future Medicine

    Dr Anke H Maitland-van der Zee

  83. Systematic Review of Pharmacogenetic Warfarin Dosing

    Article • Journal of General Internal Medicine, August 2009, Springer Science + Business Media

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  84. Genetic determinants of response to statins

    Article • Expert Review of Cardiovascular Therapy, August 2009, Taylor & Francis

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  85. Pharmacogenetics of anti-inflammatory treatment in children with asthma: rationale and design of the PACMAN cohort

    Article • Pharmacogenomics, August 2009, Future Medicine

    Dr Anke H Maitland-van der Zee

  86. Conference Scene: Initiatives on future biobanking in pharmacogenomics

    Article • Pharmacogenomics, July 2009, Future Medicine

    Dr Anke H Maitland-van der Zee

  87. Clinical impact of adducin polymorphism

    Article • Journal of Hypertension, June 2009, Wolters Kluwer Health

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  88. Systems biology in pharmacogenomic research: the way to personalized prescribing?

    Article • Pharmacogenomics, June 2009, Future Medicine

    Dr Anke H Maitland-van der Zee

  89. Reasons for non‐response in observational pharmacogenetic research

    Article • Pharmacoepidemiology and Drug Safety, May 2009, Wiley

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  90. The effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13) on the effectiveness of statins: the GenHAT study

    Article • Pharmacogenetics and Genomics, May 2009, Wolters Kluwer Health

    Dr Anke H Maitland-van der Zee

  91. AAPS–FIP Summary Workshop Report: Pharmacogenetics in Individualized Medicine: Methods, Regulatory, and Clinical Applications

    Article • The AAPS Journal, March 2009, American Association of Pharmaceutical Scientists (AAPS)

    Dr Anke H Maitland-van der Zee

  92. Pharmacogenomic insights into treatment and management of statin-induced myopathy

    Article • Genome Medicine, January 2009, Springer Science + Business Media

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  93. Interaction between the Gly460Trp α-adducin gene variant and diuretics on the risk of myocardial infarction

    Article • Journal of Hypertension, January 2009, Wolters Kluwer Health

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  94. Recruitment of participants through community pharmacies for a pharmacogenetic study of antihypertensive drug treatment

    Article • November 2008

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  95. Pharmacogenomic importance of pravastatin

    Article • Pharmacogenomics, September 2008, Future Medicine

    Dr Anke H Maitland-van der Zee

  96. Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hyperte...

    Article • Pharmacogenetics and Genomics, August 2008, Wolters Kluwer Health

    Dr Anke H Maitland-van der Zee

  97. Pharmacogenomics of coumarin anticoagulants: Are we underestimating the role of CYP2C9?

    Article • Thrombosis and Haemostasis, July 2008, Schattauer GmbH

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  98. Effectiveness of statins in the reduction of the risk of myocardial infarction is modified by the GNB3 C825T variant

    Article • Pharmacogenetics and Genomics, July 2008, Wolters Kluwer Health

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  99. Are there interactions between the Gly460Trp α-adducin gene variant and the use of diuretics?

    Article • Personalized Medicine, March 2008, Future Medicine

    Dr Anke H Maitland-van der Zee

  100. Workshop outcomes report: Initiatives to establish a European Network of pharmacogenetics/genomics and progress

    Article • European Journal of Pharmaceutical Sciences, July 2007, Elsevier

    Dr Anke H Maitland-van der Zee

  101. Epistatic Effect of Cholesteryl Ester Transfer Protein and Hepatic Lipase on Serum High-Density Lipoprotein Cholesterol Levels

    Article • The Journal of Clinical Endocrinology & Metabolism, July 2007, Endocrine Society

    Dr Anke H Maitland-van der Zee

  102. The cholesteryl ester transfer protein I405V polymorphism is associated with increased high-density lipoprotein levels and decreased risk of myocardial infarction: the Rotterdam Study

    Article • European Journal of Cardiovascular Prevention & Rehabilitation, June 2007, Oxford University Press (OUP)

    Dr Anke H Maitland-van der Zee

  103. Absence of an interaction between the angiotensin-converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: The Genetics of Hypertension-Associated Treatment (GenHAT) study

    Article • American Heart Journal, January 2007, Elsevier

    Dr Anke H Maitland-van der Zee

  104. Apoliprotein-E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS)

    Article • Acta Cardiologica, June 2006, Peeters Publishers

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  105. Wat is de relevantie van de interactie tussen verapamil en simvastatine?

    Article • January 2006, Springer Science + Business Media

    Dr Anke H Maitland-van der Zee

  106. A multilocus approach to the antihypertensive pharmacogenetics of hydrochlorothiazide

    Article • Pharmacogenetics and Genomics, May 2005, Wolters Kluwer Health

    Dr Anke H Maitland-van der Zee

  107. Pharmacogenetics of response to statins: Where do we stand?

    Article • Current Atherosclerosis Reports, May 2005, Springer Science + Business Media

    Dr Anke H Maitland-van der Zee

  108. Genetic Polymorphisms and Response to HMG-CoA Reductase Inhibitors

    Article • January 2005, Springer Science + Business Media

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  109. Pharmacogenetics in health-care practice

    Article • Pharmacy World & Science, October 2004, Springer Science + Business Media

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  110. Comparison of two methodologies to analyze exposure to statins in an observational study on effectiveness

    Article • Journal of Clinical Epidemiology, March 2004, Elsevier

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  111. Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting ??-hydroxy-??-methylglutaryl coenzyme A reductase inhibitor therapy in men

    Article • Pharmacogenetics, January 2004, Wolters Kluwer Health

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  112. Adherence to and dosing of ??-hydroxy-??-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypes

    Article • Pharmacogenetics, April 2003, Wolters Kluwer Health

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  113. 2P-0589 Influence of apolipoprotein E polymorphisms on coronary artery disease and on the efficacy of HMG-CoA reductase inhibitors in men

    Article • Atherosclerosis Supplements, January 2003, Elsevier

    Dr Anke H Maitland-van der Zee

  114. Adherence to and dosing of statins differs according to apolipoprotein E-genotypes

    Article • British Journal of Clinical Pharmacology, November 2002, Wiley

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  115. The effectiveness of hydroxy-methylglutaryl coenzyme A reductase inhibitors (statins) in the elderly is not influenced by apolipoprotein E genotype

    Article • Pharmacogenetics, November 2002, Wolters Kluwer Health

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  116. Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors

    Article • Atherosclerosis, August 2002, Elsevier

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  117. The effectiveness of HMG‐CoA reductase inhibitors in an elderly population is independent of apolipoprotein E‐genotypes

    Article • British Journal of Clinical Pharmacology, May 2002, Wiley

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  118. The association between antihypertensive drug therapies and plasma lipid levels in the general population

    Article • Journal of Human Hypertension, October 2001, Springer Science + Business Media

    Dr Anke H Maitland-van der Zee

  119. Pharmacogenetics and the Role of the Pharmacist

    Article • Journal of Research in Pharmaceutical Economics, June 2001, The Haworth Press

    Dr Anke H Maitland-van der Zee

  120. Drug-Induced Lipid Changes

    Article • Drug Safety, January 2001, Springer Science + Business Media

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  121. The interface between pharmacoepidemiology and pharmacogenetics

    Article • European Journal of Pharmacology, December 2000, Elsevier

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer